Short-term intraocular pressure trends following intravitreal ranibizumab injections for neovascular age-related macular degeneration - The role of oral acetazolamide in protecting glaucoma patients

Eye (Basingstoke)

Volumn 28, Issue 10, 2014, Pages 1218-1222

  Murray, C D ^a   Wood, D ^a   Allgar, V ^a   Walters, G ^a   Gale, R P ^a  

^a Department of Gastroenterology   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; RANIBIZUMAB;

AGE RELATED MACULAR DEGENERATION; AGED; ANALYSIS OF COVARIANCE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; MALE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

EID: 84927675275     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.180     Document Type: Article

References (14)

1. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1419-1431.
2. Brown DM, Kaiser PK, Michels M, Soubrane G, Heier JS, Kim RY et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006; 355(14): 1432-1444.
3. Ross AH, Donachie PH, Sallam A, Stratton IM, Mohamed Q, Scanlon PH et al. Which visual acuity measurements define high-quality care for patients with neovascular age-related macular degeneration treated with ranibizumab? Eye (Lond) 2013; 27(1): 56-64.
4. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K. SEVEN-UP study group. Seven-year outcomes in ranibizumab-Treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013; 120(11): 2292-2299.
5. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-Term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am JOphthalmol 2008; 146(6): 930-4 e1.
6. Falkenstein IA, Cheng L, Freeman WR. Changes of intraocular pressure after intravitreal injection of bevacizumab (avastin). Retina 2007; 27(8): 1044-1047.
7. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-Term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42(6): 807-811.
8. Frenkel RE, Mani L, Toler AR, Frenkel MP. Intraocular pressure effects of pegaptanib (Macugen) injections in patients with and without glaucoma. Am J Ophthalmol 2007; 143(6): 1034-1035.
9. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010; 128(12): 1523-1527.
10. Singer MA, Awh CC, Sadda S, Freeman WR, Antoszyk AN, Wong P et al. HORIZON: an open-label extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration. Ophthalmology 2012; 119(6): 1175-1183.
11. Schmidt-Erfurth U. Clinical safety of ranibizumab in age-related macular degeneration. Expert Opin Drug Saf 2010; 9(1): 149-165.
12. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/ timolol fixed combination on preventing the short-Term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010; 227(4): 280-284.
13. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85(7): 777-781.
14. Pallikaris IG, Kymionis GD, Ginis HS, Kounis GA, Tsilimbaris MK. Ocular rigidity in living human eyes. Invest Ophthalmol Vis Sci 2005; 46(2): 409-414.